Communication challenges for chronic metastatic cancer in an era of novel therapeutics

Qualitative Health Research

Volumn 23, Issue 7, 2013, Pages 863-875

  Thorne, Sally E ^a   Oliffe, John L ^a   Oglov, Valerie ^a   Gelmon, Karen ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

cancer; cancer, psychosocial aspects; communication; interpretive description; relationships, health care; survivorship

Indexed keywords

ADULT; AGED; CHRONIC DISEASE; FEMALE; HUMAN; HUMAN RELATION; INTERPERSONAL COMMUNICATION; INTERVIEW; MALE; METASTASIS; MIDDLE AGED; NEOPLASMS; PATHOLOGY; PATIENT CARE; PERSONALIZED MEDICINE; PSYCHOLOGY; ARTICLE; CANCER, PSYCHOSOCIAL ASPECTS; INTERPRETIVE DESCRIPTION; NEOPLASM; PSYCHOLOGICAL ASPECT; RELATIONSHIPS, HEALTH CARE; SURVIVORSHIP;

ADULT; AGED; CHRONIC DISEASE; COMMUNICATION; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PATIENT-CENTERED CARE; PROFESSIONAL-PATIENT RELATIONS;

CANCER; CANCER, PSYCHOSOCIAL ASPECTS; COMMUNICATION; INTERPRETIVE DESCRIPTION; RELATIONSHIPS, HEALTH CARE; SURVIVORSHIP;

EID: 84878053895     PISSN: 10497323     EISSN: 15527557     Source Type: Journal    
DOI: 10.1177/1049732313483926     Document Type: Article

References (61)

1. Aggarwa S.. Targeted cancer therapies. Nature Reviews Drug Discovery. 2010 ; 9: 427-428
2. Arora N. K.. Interacting with cancer patients: The significance of physicians' communication behavior. Social Science & Medicine. 2003 ; 57 (5). 791-806 (Pubitemid 36870719)
3. Bach P. B.. Limits on Medicare's ability to control rising spending on cancer drugs. New England Journal of Medicine. 2009 ; 360: 626-633
4. Back A. L., Arnold R. M., Baile W. F., Tulsky J. A., Fryer-Edwards K.. Approaching difficult communication tasks in oncology. CA: A Cancer Journal for Clinicians. 2005 ; 55 (3). 164-177 (Pubitemid 40826486)
5. Bahti T.. Coping issues among people living with advanced cancer. Seminars in Oncology Nursing ; 2010 ; 2010. 175.
6. Baile W. F., Aaron J.. Patient-physician communication in oncology: Past, present, and future. Current Opinion in Oncology. 2005 ; 17 (4). 331-335 (Pubitemid 40904416)
7. Bober S. L., Recklitis C. J., Campbell E. G., Park E. R., Kutner J. S., Najita J. S., Diller L.. Caring for cancer survivors: A survey of primary care physicians. Cancer. 2009 ; 115: 4409-4418
8. Butow P.. The communication goals and needs of cancer patients: A review. Psycho-Oncology. 2005 ; 14: 846-847 (Pubitemid 41489502)
9. Cao Y., DePinho R. A., Ernst M., Vousden K.. Cancer research: Past, present and future. Nature Reviews Cancer. 2011 ; 11: 749-754
10. Carlson L. E., Bultz B. D.. Benefits of psychosocial oncology care: Improved quality of life and medical cost effect. Health and Quality of Life Outcomes. 2003 ; 1 (8). 1-9
11. Collaza M., de Azambuja E., Personeni N., Lebrun F., Piccart M. J., Cardozo F.. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist. 2007 ; 12: 253-270 (Pubitemid 46556792)
12. Conrad P., Barker K. K.. The social construction of illness: Key insights and policy implications. Journal of Health and Social Behavior. 2010 ; 51: S67 - S79
13. Cunningham A. J.. The mind-cancer connection: Can the patient's mental state assist in healing?. Oncology Exchange. 2004 ; 3 (3). 19-26
14. Davis C., Abraham J.. Desperately seeking cancer drugs: Explaining the emergence and outcomes of accelerated pharmaceutical regulation. Sociology of Health & Illness. 2011 ; 33 (5). 731-747
15. DeVita V. T., Canellos G. P.. Hematology in 2010: New therapies and standard of care in oncology. Nature Reviews Clinical Oncology. 2011 ; 8: 67-68
16. EpsteinR. M.StreetR. L. (2007). Patient-centered communication in cancer care: Promoting healing and reducing suffering (NIH Pub. No. 07-6225). Bethesda, MD: National Institutes of Health. Retrieved from http://outcomes.cancer.gov/ areas/pcc/communication/monograph.html
17. Feldman-Stewart D., Brundage M. D., Tishelman C.. A conceptual framework for patient-professional communication: An application to the cancer context. Psycho-Oncology. 2005 ; 14 (10). 801-809 (Pubitemid 41489497)
18. Feuerstein M.. Defining cancer survivorship. Journal of Cancer Survivorship. 2007 ; 1: 5-7
19. Frenkel M., Ari S. L., Engebretson J., Peterson N., Maimon Y., Cohen L., Kacen L.. Activism among exceptional patients with cancer. Supportive Care in Cancer. 2011 ; 19: 1125-1132
20. Gelmon K.. Milestones in personalised medicine - Trastuzumab. Lancet Oncology. 2008 ; 9: 698
21. Gelmon K. A., Mackey J., Verma S., Gertler S. Z., Bangemann N., Klimo P., Dias R.. Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories. Clinical Breast Cancer. 2004 ; 5 (1). 52-58 (Pubitemid 38821191)
22. Grunfeld E., Earle C. C.. The interface between primary and oncology specialty care: Treatment through survivorship. Journal of the National Cancer Institute Monograph. 2010 ; 40: 25-30
23. Haylock P. J.. Advanced cancer: Emergence of a new survivor population. Seminars in Oncology Nursing ; 2010 ; 2010. 144.
24. Higgins M. J., Baselga J.. Breast cancer in 2010: Novel targets and therapies for a personalized approach. Nature Reviews Clinical Oncology. 2011 ; 8: 65-66
25. Jenkins V. A., Trapala I. S., Parlour L., Langridge C. I., Fallowfield L. J.. The views of patients and the general public about expensive anti-cancer drugs in the NHS: A questionnaire-based study. Journal of the Royal Society of Medicine. 2011 ; 2 (69). 1-8
26. Jiang Y., Wang M.. Personalized medicine in oncology: Tailoring the right drug to the right patient. Biomarker Medicine. 2010 ; 4 (4). 523-533
27. Kaser E., Shaw J., Marven M., Swinburne L., Boyle F.. Communication about high-cost drugs in oncology: The patient view. Annals of Oncology. 2010 ; 21 (9). 1910-1914
28. Lage A., Crombet T.. Control of advanced cancer: The road to chronicity. International Journal of Environmental Research and Public Health. 2011 ; 8 (3). 683-697
29. Liamputtong P. Researching the vulnerable. London: Sage ; 2007 :
30. Lovly C. M., David P.. Lung cancer in 2010: One size does not fit all. Nature Reviews Clinical Oncology. 2011 ; 8: 68-70
31. Ma W. W., Adjei A. A.. Novel agents on the horizon for cancer therapy. CA: A Cancer Journal for Clinicians. 2009 ; 59: 111-137
32. MacaulayJ.KristalL. (2009). Optimizing access to cancer drugs for Canadians. Ottawa, ON, Canada: Public Policy Forum. Retrieved from http://www.ccanceraction.ca/wp-content/uploads/2010/11/1-Symposium.pdf
33. McCorkle R., Ercolano E., Lazenby M., Schulman-Green D., Schilling L. S., Lorig K., Wagner E.. Self-management: Enabling and empowering patients living with cancer as a chronic illness. CA: A Cancer Journal for Clinicians. 2011 ; 61 (1). 50-62
34. Miller K., Merry B., Miller J.. Seasons of survivorship revisited. Cancer Journal. 2008 ; 14 (6). 369-374
35. From cancer patient to cancer survivor: Lost in transition. Washington, DC: National Academies Press ; 2005 :
36. Naus M. J., Ishler M. D., Parrott C. E., Kovacs S. A.. Cancer survivor adaptation model: Conceptualizing cancer as a chronic illness. Journal of Clinical Psychology. 2009 ; 65 (12). 1350-1359
37. Nekhlyudov L.. "Doc, should I see you or my oncologist?": A primary care perspective on opportunities and challenges in providing comprehensive care for cancer survivors. Journal of Clinical Oncology. 2009 ; 27 (15). 2424-2426
38. Phillips J. L., Currow D. C.. Cancer as a chronic disease. Collegian. 2010 ; 17 (2). 47-50
39. PriestL. (2010, March29). Herceptin: A wonder drug, but not a miracle. Globe & Mail. Retrieved from http://www.bcam.qc.ca/content/herceptin-wonder- drug-not-miracle
40. Richards L. Handling qualitative data: A practical guide. London: Sage ; 2005 :
41. Roché H., Vahdat L. T.. Treatment of metastatic breast cancer: Second line and beyond. Annals of Oncology. 2010 ; 22 (5). 1000-1010
42. Rosman S.. Recovered from cancer but still ill: Strategies used to legitimise extreme persistent fatigue in disease-free cancer patients. European Journal of Cancer Care. 2009 ; 18 (1). 28-36
43. Roukos D. H.. Systems medicine: A real approach for future personalized oncology?. Pharmacogenomics. 2010 ; 11 (3). 283-287
44. Schofield P. E., Butow P. N.. Towards better communication in cancer care: A framework for developing evidence-based interventions. Patient Education and Counseling. 2004 ; 55 (1). 32-39 (Pubitemid 39349781)
45. Sharma M. R., Schilsky R. L.. GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy. Nature Reviews Clinical Oncology. 2011 ; 8: 70-72
46. Shulman L., Jacobs L., Greenfield S., Jones B., McCabe M., Syrjala K., Ganz P. A.. Cancer care and cancer survivorship care in the United States: Will we be able to care for these patients in the future?. Journal of Oncology Practice. 2009 ; 5 (3). 119-123
47. SislerJ.McCormack-SpeakP. (2009). Bridging the gap between primary care and the cancer system. Canadian Family Physician, 55, 273-278. Retrieved from http://www.cfp.ca/content/55/3/273.long
48. Suhasini J., Ashis K. T., Bodhisattwa M., Alpana S.. Oncoproteomics. Clinica Chimica Acta. 2010 ; 412 (3-4). 217-226
49. Tattersall M. H., Butow P. N., Clayton J. M.. Insights from cancer patient communication research. Hematology/Oncology Clinics of North America. 2002 ; 16 (3). 731-743 (Pubitemid 34827378)
50. Thorne S.. Toward methodological emancipation in applied health research. Qualitative Health Research. 2011 ; 21: 443-453
51. Thorne S., Armstrong E.-A., Harris S. R., Hislop T. G., Kim-Sing C., Oglov V., Stajduhar K. I.. Patient real-time and 12-month retrospective perceptions of difficult communications in the cancer diagnostic period. Qualitative Health Research. 2009 ; 19: 1383-1394
52. Thorne S., Reimer Kirkham S., MacDonald-Emes J.. Interpretive description: A non-categorical qualitative alternative for developing nursing knowledge. Research in Nursing & Health. 1997 ; 20 (2). 169-177 (Pubitemid 127453583)
53. ThorneS.Reimer KirkhamS.O'Flynn-MageeK. (2004). The analytic challenge in interpretive description. International Journal of Qualitative Methods, 3(1), 1-11. Retrieved from http://www.ualberta.ca/∼iiqm/backissues/3-1/pdf/ thorneetal.pdf
54. Thorne S. E. Interpretive description. Walnut Creek, CA: Left Coast Press ; 2008 :
55. Thorne S. E., Bultz B. D., Baile W. F.. Is there a cost to poor communication in cancer care? A critical review of the literature. Psycho-Oncology. 2005 ; 14 (10). 875-884 (Pubitemid 41489507)
56. Thorne S. E., Hislop T. G., Armstrong E. A., Oglov V.. Cancer care communication: The power to harm and the power to heal?. Patient Education & Counseling. 2008 ; 71 (1). 34-40
57. Tighe M., Molassiotis A., Morris J., Richardson J.. Coping, meaning and symptom experience: A narrative approach to the overwhelming impacts of breast cancer in the first year following diagnosis. European Journal of Oncology Nursing. 2011 ; 15: 226-232
58. Vahdat L. T.. Novel combinations for the treatment of metastatic breast cancer. Cancers. 2010 ; 2: 1-19
59. Vardy J., Tannock I. F.. Quality of cancer care. Annals of Oncology. 2004 ; 15 (7). 1001-1006 (Pubitemid 39089774)
60. VermaS.LavasaniS.MackeyJ.PritchardK.ClemonsM.DentS.RaysonD. (2010). Optimizing the management of her2-positive early breast cancer: The clinical reality. Current Oncology, 17(4), 20-33. Retrieved from http://www.current- oncology.com/index.php/oncology/article/view/700
61. Younes A.. Beyond chemotherapy: New agents for targeted treatment of lymphoma. Nature Reviews Clinical Oncology. 2011 ; 8: 85-96